JSP chooses Amneal after ceasing Lannett
Amneal Pharmaceuticals is to stake a claim in “one of the most compelling generic product markets in the United States today” by signing a 10-year licence and supply agreement with Jerome Stevens Pharmaceuticals (JSP) for levothyroxine sodium tablets, after the family-owned company opted against renewing its existing agreement with Lannett (see page 14).
You may also be interested in...
Amneal Starts Seeking International Partners
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.